# Tirzepatide 2.5 mg vs 5 mg in Japanese Adults Without Diabetes | This GLP In 112 non-diabetic Japanese adults, tirzepatide 2.5 mg produced 15.3% weight loss against 16.1% at 5 mg, with adverse events of 35% against 50%, and no randomization. Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-low-dose-self-selected Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Tirzepatide 2.5 mg vs 5 mg in Japanese Adults Without Diabetes Tirzepatide at 2.5 mg matched 5 mg on weight loss over six months in 112 adults. Patients picked their own dose, which is why the comparison cannot settle it. [This GLP Editorial Team](https://thisglp.com/about)September 20266 min readUpdated September 2026 2.5 mg against 5 mg, six months · weight lost · 15.3% at 2.5 mg · 16.1% at 5 mg · had an adverse event · 35% at 2.5 mg · 50% at 5 mg · 112 adults. Nobody was assigned a dose — each was chosen. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - 112 non-diabetic Japanese adults on tirzepatide, 58 staying at 2.5 mg and 54 moving to 5 mg after four weeks. - The dose was decided between patient and clinician, not randomly assigned. - At six months the primary outcome was met by 62.1% against 63.0%, hazard ratio 0.93, 95% CI 0.58 to 1.49. - Mean weight loss was 15.3% against 16.1%, p = 0.563. - Adverse events were more frequent at 5 mg: 50% against 35%, mostly gastrointestinal. A study suggesting the lowest maintenance dose does almost as much as the next one up would matter on a market where the dose is what the price is attached to. This one cannot establish it, and the reason is in the methods rather than the results — the same place [the randomized dose comparison](https://thisglp.com/research/is-a-higher-semaglutide-dose-worth-it) has its answer. ## How the two groups were formed Everyone started at 2.5 mg weekly. After four weeks, the dose was either held or increased to 5 mg, based on shared decision-making between the patient and their clinician. [\[1\]](https://thisglp.com/research/tirzepatide-low-dose-self-selected#ref-1) That produced 58 people at 2.5 mg and 54 at 5 mg. Nobody was randomized. A person doing well at four weeks has little reason to escalate, and a person struggling with nausea has a reason not to — so the low-dose group is enriched for good early responders and for people who would have tolerated more poorly. Both push the comparison the same way. Which findings survive that, and which do not The efficacy comparison does not. 62.1% against 63.0% and 15.3% against 16.1% are exactly what you would expect if the people who stayed low were the ones already on track, and no statistical adjustment recovers a randomization that never happened. The tolerability comparison is sturdier: adverse events ran 50% at 5 mg against 35% at 2.5 mg, and if anything the selection works against that finding, since people who reacted badly early were the ones who stayed at the lower dose — the mirror of [a null that cannot be trusted](https://thisglp.com/research/does-a-glp1-affect-surgery-outcomes), where the bias runs toward the result rather than away from it. ## Why 15.3% is higher than you have seen Mean body mass index at entry was 30.8 — considerably lower than the Western obesity trials — in a Japanese cohort, alongside standardized dietary and exercise counseling. Dietary adherence was 96.4%. Exercise adherence was 37.5%. So the lifestyle arm of this was very largely a diet arm, which is worth knowing before reading the weight figures as the drug’s alone — and it makes the result hard to carry to a reader at a different body size with no dietitian attached, in the same way [a trial run at locally defined entry criteria](https://thisglp.com/research/what-bmi-do-you-need-for-a-glp1) does not transfer. ## What it is good for Two things. The tolerability gap is real and useful: half the people at 5 mg had an adverse event against a third at 2.5 mg, almost all gastrointestinal. And it establishes that low-dose maintenance is a strategy clinicians are actually using, which is a fact about practice rather than about efficacy. Whether a seller’s price follows the dose upward is a separate question and one this site can answer — [who publishes a ladder at all](https://thisglp.com/tools/published-dose-ladders) decides whether a buyer can even see the difference. Nothing here is a reason to choose a dose; that is a prescriber’s call. ## Frequently asked Does 2.5 mg work as well as 5 mg? This study found 15.3% against 16.1% weight loss, but patients chose their own dose with their clinician. The low-dose group is enriched for people already doing well, so the comparison cannot answer it. Which finding is reliable? The tolerability difference: 50% of the 5 mg group had an adverse event against 35% at 2.5 mg. Selection works against that result rather than for it. Why was the weight loss so high? Mean body mass index at entry was 30.8 in a Japanese cohort, with standardized dietary counseling at 96.4% adherence. Exercise adherence was 37.5%. Should I ask to stay on a lower dose? That is a prescriber's decision. What this study shows is that low-dose maintenance is a strategy in use, not that it produces equal results. ## Sources 1. \[1\] Amioka M, et al. (2026). Low-Dose Tirzepatide for Obesity: Comparative Efficacy of 2.5 mg Versus 5 mg in Non-Diabetic Japanese Adults Diabetes, Obesity and Metabolism. [PMID 42521631](https://pubmed.ncbi.nlm.nih.gov/42521631/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)